Bank of America just raised its EUR/USD forecast
SUNNYVALE, Calif. - Robotic surgery pioneer Intuitive (NASDAQ:ISRG), a $183.59 billion market cap leader with impressive 19% year-over-year revenue growth, demonstrated telesurgery capabilities by connecting surgeons across the Atlantic during the Society of Robotic Surgery conference in Strasbourg, France, according to a company press release. InvestingPro analysis shows the company maintains a "GREAT" financial health score, reflecting its strong market position.
During Wednesday’s demonstration, surgeons Doug Stoddard in Georgia and Andrea Pakula in France collaboratively operated on an advanced tissue model using a dual console da Vinci 5 system. The surgeons passed control of surgical instruments back and forth while separated by more than 4,000 miles, with both experiencing force feedback that allowed them to feel instrument pressure on the tissue model.
"Telesurgery is an area Intuitive has been thoughtfully innovating in for many years," said Intuitive CEO Dave Rosa at the conference. "It is a capability that has the potential to improve patient access to minimally invasive care." This innovation-driven approach has helped the company maintain an impressive 67% gross profit margin, according to InvestingPro data.
The concept of telesurgery has been technically feasible since 2001 when the first transatlantic procedure, called Operation Lindbergh, was performed between the U.S. and France. Brian Miller, Intuitive’s executive vice president who supported that original operation, noted that successful telesurgery requires both high-performing network infrastructure and robotic systems designed for remote collaboration.
The telesurgery software demonstrated on the da Vinci 5 system is still in development and has not received regulatory clearance. It is not currently available for sale in the U.S. or European Union.
Intuitive, founded 30 years ago, reports that surgeons have performed nearly 17 million procedures using its da Vinci systems, with almost 90,000 surgeons trained on the technology. While the stock currently trades above its InvestingPro Fair Value, investors can access detailed valuation analysis and 13 additional ProTips through the comprehensive Pro Research Report, available for over 1,400 US stocks.
In other recent news, Intuitive received U.S. Food and Drug Administration clearance for its Vessel Sealer Curved instrument, designed for use with its da Vinci robotic surgical systems. This advanced instrument allows for precise procedures, including the transection of lymphatic and blood vessels up to 7mm in diameter. Additionally, Intuitive Surgical gained early CE mark approval for its DV5 system in Europe, which is expected to positively impact the company’s growth potential, according to Leerink Partners. Meanwhile, Bernstein SocGen Group reiterated its Outperform rating for Intuitive Surgical, citing a promising product cycle and potential margin improvements. Conversely, Deutsche Bank downgraded the stock to a Sell rating, adjusting its price target to $440, reflecting concerns about the company’s market position. Erste Group upgraded Intuitive Surgical to a Buy rating, forecasting an uptick in turnover and profits in 2025 despite current challenges from tariffs. These developments highlight various analyst perspectives on Intuitive Surgical’s future growth prospects and market dynamics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.